-
1
-
-
67349126033
-
Uroplakins in urothelial biology, function, and disease
-
Wu XR, Kong XP, Pellicer A, Kreibich G, Sun TT. Uroplakins in urothelial biology, function, and disease. Kidney Int. 2009; 75; 1153-1165.
-
(2009)
Kidney Int.
, vol.75
, pp. 1153-1165
-
-
Wu, X.R.1
Kong, X.P.2
Pellicer, A.3
Kreibich, G.4
Sun, T.T.5
-
2
-
-
34247630071
-
Placental s100 (s100p) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray
-
Higgins JP, Kaygusuz G, Wang L et al. Placental s100 (s100p) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am. J. Surg. Pathol. 2007; 31; 673-680.
-
(2007)
Am. J. Surg. Pathol.
, vol.31
, pp. 673-680
-
-
Higgins, J.P.1
Kaygusuz, G.2
Wang, L.3
-
3
-
-
84891623727
-
GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors
-
Miettinen M, McCue PA, Sarlomo-Rikala M et al. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. Am. J. Surg. Pathol. 2013; 38; 13-22.
-
(2013)
Am. J. Surg. Pathol.
, vol.38
, pp. 13-22
-
-
Miettinen, M.1
McCue, P.A.2
Sarlomo-Rikala, M.3
-
4
-
-
84876487361
-
Hilar cholangiocarcinoma and pancreatic ductal adenocarcinoma share similar histopathologies, immunophenotypes, and development-related molecules
-
Gandou C, Harada K, Sato Y et al. Hilar cholangiocarcinoma and pancreatic ductal adenocarcinoma share similar histopathologies, immunophenotypes, and development-related molecules. Hum. Pathol. 2013; 44; 811-821.
-
(2013)
Hum. Pathol.
, vol.44
, pp. 811-821
-
-
Gandou, C.1
Harada, K.2
Sato, Y.3
-
5
-
-
0034424842
-
Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas
-
Kaufmann O, Volmerig J, Dietel M. Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas. Am. J. Clin. Pathol. 2000; 113; 683-687.
-
(2000)
Am. J. Clin. Pathol.
, vol.113
, pp. 683-687
-
-
Kaufmann, O.1
Volmerig, J.2
Dietel, M.3
-
6
-
-
0036305276
-
Uroplakin-III to distinguish primary vulvar Paget disease from Paget disease secondary to urothelial carcinoma
-
Brown HM, Wilkinson EJ. Uroplakin-III to distinguish primary vulvar Paget disease from Paget disease secondary to urothelial carcinoma. Hum. Pathol. 2002; 33; 545-548.
-
(2002)
Hum. Pathol.
, vol.33
, pp. 545-548
-
-
Brown, H.M.1
Wilkinson, E.J.2
-
7
-
-
0036859760
-
Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma
-
Mhawech P, Uchida T, Pelte MF. Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma. Hum. Pathol. 2002; 33; 1136-1140.
-
(2002)
Hum. Pathol.
, vol.33
, pp. 1136-1140
-
-
Mhawech, P.1
Uchida, T.2
Pelte, M.F.3
-
8
-
-
0037215340
-
Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas
-
Parker DC, Folpe AL, Bell J et al. Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas. Am. J. Surg. Pathol. 2003; 27; 1-10.
-
(2003)
Am. J. Surg. Pathol.
, vol.27
, pp. 1-10
-
-
Parker, D.C.1
Folpe, A.L.2
Bell, J.3
-
9
-
-
84870860776
-
Selective immunohistochemical markers to distinguish between metastatic high-grade urothelial carcinoma and primary poorly differentiated invasive squamous cell carcinoma of the lung
-
Gruver AM, Amin MB, Luthringer DJ et al. Selective immunohistochemical markers to distinguish between metastatic high-grade urothelial carcinoma and primary poorly differentiated invasive squamous cell carcinoma of the lung. Arch. Pathol. Lab. Med. 2012; 136; 1339-1346.
-
(2012)
Arch. Pathol. Lab. Med.
, vol.136
, pp. 1339-1346
-
-
Gruver, A.M.1
Amin, M.B.2
Luthringer, D.J.3
-
10
-
-
84904465568
-
A newly developed anti-uroplakin II monoclonal antibody with increased sensitivity in urothelial carcinoma of the bladder
-
Hoang L, Qi W, Bremer R et al. A newly developed anti-uroplakin II monoclonal antibody with increased sensitivity in urothelial carcinoma of the bladder. Mod. Pathol. 2013; 26(Suppl 2); 1A-534A.
-
(2013)
Mod. Pathol.
, vol.26
, Issue.2 SUPPL
-
-
Hoang, L.1
Qi, W.2
Bremer, R.3
-
11
-
-
84863409904
-
P63, CK7, PAX8 and INI-1: an optimal immunohistochemical panel to distinguish poorly differentiated urothelial cell carcinoma from high-grade tumours of the renal collecting system
-
Carvalho JC, Thomas DG, McHugh JB, Shah RB, Kunju LP. P63, CK7, PAX8 and INI-1: an optimal immunohistochemical panel to distinguish poorly differentiated urothelial cell carcinoma from high-grade tumours of the renal collecting system. Histopathology 2012; 60; 597-608.
-
(2012)
Histopathology
, vol.60
, pp. 597-608
-
-
Carvalho, J.C.1
Thomas, D.G.2
McHugh, J.B.3
Shah, R.B.4
Kunju, L.P.5
-
12
-
-
84865485319
-
Carcinoma of the collecting ducts of Bellini and renal medullary carcinoma: clinicopathologic analysis of 52 cases of rare aggressive subtypes of renal cell carcinoma with a focus on their interrelationship
-
Gupta R, Billis A, Shah RB et al. Carcinoma of the collecting ducts of Bellini and renal medullary carcinoma: clinicopathologic analysis of 52 cases of rare aggressive subtypes of renal cell carcinoma with a focus on their interrelationship. Am. J. Surg. Pathol. 2012; 36; 1265-1278.
-
(2012)
Am. J. Surg. Pathol.
, vol.36
, pp. 1265-1278
-
-
Gupta, R.1
Billis, A.2
Shah, R.B.3
-
13
-
-
84888068230
-
The role of GATA binding protein 3 in the differential diagnosis of collecting duct and upper tract urothelial carcinomas
-
Gonzalez-Roibon N, Albadine R, Sharma R et al. The role of GATA binding protein 3 in the differential diagnosis of collecting duct and upper tract urothelial carcinomas. Hum. Pathol. 2013; 44; 2651-2657.
-
(2013)
Hum. Pathol.
, vol.44
, pp. 2651-2657
-
-
Gonzalez-Roibon, N.1
Albadine, R.2
Sharma, R.3
-
14
-
-
84885022366
-
GATA3 expression in paragangliomas: a pitfall potentially leading to misdiagnosis of urothelial carcinoma
-
So JS, Epstein JI. GATA3 expression in paragangliomas: a pitfall potentially leading to misdiagnosis of urothelial carcinoma. Mod. Pathol. 2013; 26; 1365-1370.
-
(2013)
Mod. Pathol.
, vol.26
, pp. 1365-1370
-
-
So, J.S.1
Epstein, J.I.2
-
15
-
-
84888129675
-
Is GATA3 expression maintained in regional metastases? A study of paired primary and metastatic urothelial carcinomas
-
Zhao L, Antic T, Witten D et al. Is GATA3 expression maintained in regional metastases? A study of paired primary and metastatic urothelial carcinomas. Am. J. Surg. Pathol. 2013; 37; 1876-1881.
-
(2013)
Am. J. Surg. Pathol.
, vol.37
, pp. 1876-1881
-
-
Zhao, L.1
Antic, T.2
Witten, D.3
-
16
-
-
84866607353
-
Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung
-
Chang A, Amin A, Gabrielson E et al. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung. Am. J. Surg. Pathol. 2012; 36; 1472-1476.
-
(2012)
Am. J. Surg. Pathol.
, vol.36
, pp. 1472-1476
-
-
Chang, A.1
Amin, A.2
Gabrielson, E.3
-
17
-
-
84872683637
-
Immunohistochemical profile to distinguish urothelial from squamous differentiation in carcinomas of urothelial tract
-
Gulmann C, Paner GP, Parakh RS et al. Immunohistochemical profile to distinguish urothelial from squamous differentiation in carcinomas of urothelial tract. Hum. Pathol. 2013; 44; 164-172.
-
(2013)
Hum. Pathol.
, vol.44
, pp. 164-172
-
-
Gulmann, C.1
Paner, G.P.2
Parakh, R.S.3
-
18
-
-
33646250894
-
Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betae12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma
-
Kunju LP, Mehra R, Snyder M, Shah RB. Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betae12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma. Am. J. Clin. Pathol. 2006; 125; 675-681.
-
(2006)
Am. J. Clin. Pathol.
, vol.125
, pp. 675-681
-
-
Kunju, L.P.1
Mehra, R.2
Snyder, M.3
Shah, R.B.4
|